Stifel Financial Corp raised its position in West Pharmaceutical Services Inc. (NYSE:WST) by 14.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 23,776 shares of the medical instruments supplier’s stock after purchasing an additional 2,985 shares during the period. Stifel Financial Corp’s holdings in West Pharmaceutical Services were worth $2,326,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the business. Gideon Capital Advisors Inc. purchased a new position in West Pharmaceutical Services in the 4th quarter valued at $403,000. Natixis Advisors L.P. purchased a new position in West Pharmaceutical Services in the 4th quarter valued at $1,019,000. Berman Capital Advisors LLC purchased a new position in West Pharmaceutical Services in the 4th quarter valued at $27,000. Dimensional Fund Advisors LP lifted its holdings in West Pharmaceutical Services by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 353,571 shares of the medical instruments supplier’s stock valued at $34,658,000 after purchasing an additional 4,225 shares in the last quarter. Finally, United Services Automobile Association lifted its holdings in West Pharmaceutical Services by 12.3% in the 4th quarter. United Services Automobile Association now owns 51,234 shares of the medical instruments supplier’s stock valued at $5,022,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors own 94.39% of the company’s stock.
Separately, Zacks Investment Research lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Friday.
West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, February 14th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.01. West Pharmaceutical Services had a return on equity of 15.89% and a net margin of 12.05%. The business had revenue of $422.50 million during the quarter, compared to the consensus estimate of $432.38 million. During the same period last year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities analysts forecast that West Pharmaceutical Services Inc. will post 2.85 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Wednesday, April 17th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date of this dividend is Tuesday, April 16th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.
TRADEMARK VIOLATION WARNING: “West Pharmaceutical Services Inc. (WST) Shares Bought by Stifel Financial Corp” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/stifel-financial-corp-has-2-33-million-position-in-west-pharmaceutical-services-inc-wst.html.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: What is the 52-week high/low?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.